Last reviewed · How we verify
NCT05754242: VITACTOH
Ascorbic Acid to Prevent Postreperfusion Syndrome in Liver Transplantation
Phase 2 trial testing Ascorbic acid in Liver Transplantation in 70 participants. Status unknown.
30 June 2023
Quick facts
| Lead sponsor | Hospital Universitario Ramon y Cajal |
|---|---|
| Phase | Phase 2 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | prevention |
| Enrollment | 70 |
| Start date | 17 November 2020 |
| Primary completion | 30 June 2023 |
| Estimated completion | 30 July 2023 |
| Sites | 1 location across Spain |
Drugs / interventions tested
- Ascorbic acid (ASCORBIC ACID) — full drug profile →
- 0.9% Saline solution
Conditions studied
- Liver Transplantation — all drugs for Liver Transplantation →
- Postreperfusion Syndrome — all drugs for Postreperfusion Syndrome →
- Ascorbic Acid — all drugs for Ascorbic Acid →
Sponsor
Hospital Universitario Ramon y Cajal
Who can join
Adults 18 to 67, any sex, with Liver Transplantation or Postreperfusion Syndrome. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this clinical trial is to test the efficacy of intravenous ascorbic acid in preventing the postreperfusion syndrome in liver transplantation. The main questions it aims to answer are: * Can intravenous ascorbic acid prevent postreperfusion syndrome in liver transplantation ? * Can ascorbic acid decrease the incidence of liver graft dysfunction after liver transplantation? * Can ascorbic acid decreased the incidence of postoperative complications after liver transplantation ? Participants will receive 1.5 g of intravenous ascorbic acid diluted in 100 ml of saline or 100 ml of saline alone, during the anhepatic phase of liver transplantation before reperfusion of the new graft. Researchers will compared the incidence of postreperfusion syndrome in both groups.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Intravenous Ascorbic Acid for the Prevention of Postreperfusion Syndrome in Orthotopic Liver Transplantation: Protocol for a Randomized Controlled Trial.
Gajate L, de la Hoz I, Espiño M, Martin Gonzalez MDC, et al · · 2023 · cited 2× · PMID 38100226 · DOI 10.2196/50091 -
A randomized trial of ascorbic acid for the prevention of post-reperfusion syndrome during liver transplantation.
Gajate Martín L, de la Hoz I, Martín M, Fernández C, et al · · 2025 · PMID 40719561 · DOI 10.1097/hc9.0000000000000777
Verify or expand the search:
- PubMed search for NCT05754242
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Ascorbic acid
Trials testing the same drug.
- NCT06936592 — How Can Prefabricated Membranes Load Ascorbic Acid Can Curtail Gingival Recession? · NA · not yet recruiting
- NCT04516681 — Combination of IV Ascorbic Acid and Adebrelimab in Metastatic Colorectal Cancer · Phase 3 · recruiting
- NCT05849129 — Adjunctive Intravenous Ascorbic Acid for Advanced Non-Small Cell Lung Cancer · Phase 2 · recruiting
- NCT06443151 — Role of Endothelial Function in SCI CVD Risk · recruiting
- NCT06384833 — Combination of Vitamin C and N-Acetylcysteine to Improve Functional Outcome After Rotator Cuff Repair · Phase 4 · not yet recruiting
Other recruiting trials for Liver Transplantation
Currently open trials in the same condition.
- NCT07157631 — Efficacy and Safety of Tranexamic Acid in Adult Liver Transplantation---ESTA Trial · NA · recruiting
- NCT07123740 — Comparison of the Postoperative Analgesic Effects of ITM and Bi-level ESPB in Liver Transplantation Donors · NA · recruiting
- NCT06717919 — HOPE Against Cancer Recurrence in HCC · Phase 4 · recruiting
- NCT06868589 — Reducing Pain With Methadone and Ketamine in Liver Transplant · Phase 4 · active not recruiting
- NCT06874296 — Assessing Declined Liver Grafts With Normothermic Machine Perfusion to Reduce Transplant Waiting Time · NA · recruiting
Other Hospital Universitario Ramon y Cajal trials
Trials by the same sponsor.
- NCT07001215 — Effect of CPAP Versus APAP in Patients With Obesity Undergoing Bariatric Surgery Protocol · NA · not yet recruiting
- NCT05268471 — Cost-effectiveness Analysis and Conditional Response to the Effect of Positional Devices in Obstructive Sleep Apnea · NA · unknown
- NCT04690179 — Effects of Sarcopenia and Sarcopenic Obesity in Complex Abdominal Wall Surgery · unknown
- NCT05435521 — Impact of a Personalized Multicomponent Exercise Program in Real Conditions Among Older Adults With HIV · NA · unknown
- NCT04935450 — Pulmonary Inflammation in COVID-19 ARDS · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05754242 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hospital Universitario Ramon y Cajal
- Last refreshed: 3 March 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05754242.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing